Resmed shares open higher as Q1 revenue gains 6% to $2b
ResMed reported a 6% revenue increase to $1.4B in Q1, with shares up 3.9% to $36.76. GAAP EPS rose 23% to $2.92, and gross margins improved. Operating cash flow was $422M, with $1B returned to shareholders.
How this was made
The 30-second read
Why it matters
The earnings beat and strong cash flow support a bullish outlook, but the sizable shareholder return could be a point of debate among investors.
Market read
ResMed's earnings beat and cash‑return program provide a clear catalyst for short‑term price movement and influence the broader healthcare sector.
What to watch
potential regulatory scrutiny in key markets and competitive pressure from emerging sleep‑therapy devices
Background
ResMed announced its first‑quarter results, showing a 6% revenue increase to $1.4 billion, GAAP EPS of $2.92, and a 3.9% pre‑market share rise. The company returned about $1 billion to shareholders via dividends and buybacks after selling MatrixCare.
Ticker impact
ResMed reported Q1 revenue up 6% to $1.4B, GAAP EPS $2.92, and shares rose 3.9% pre‑market.
likely upside as market prices in the revenue and earnings beat
Revenue and EPS exceeded expectations, share price already up, suggesting further buying pressure.
Market effects
strengthens outlook for sleep‑apnea and broader medical‑device sector
positive for US healthcare equities
moderate, given ResMed's worldwide operations
Counterpoint
large shareholder return ($1B) may limit growth capital and raise concerns about cash utilization
Key entities
- companyResMed Inc.
US‑listed medical‑equipment company reporting Q1 earnings
- business unitMatrixCare
Software business recently sold by ResMed, proceeds used for shareholder returns
